Guy Rosenthal, Ph.D.
Guy Rosenthal is the Business Development Officer of Biopharmaceuticals at UCLA Technology Development Group. In his role, Guy leads commercial and business development efforts, amongst others, to advance the commercialization of immuno-oncology, immunology, and computational biology programs.
Previously, Guy served as the Manager of Academic Affairs and Networks at Teva Pharmaceutical Industries (NASDAQ: TEVA) Global R&D headquarters, where he lead global external innovation with Teva's academic partners. In addition, Guy lead search and evaluation efforts of academic technologies reporting to Teva President of Global R&D and Chief Scientific Officer. Prior to that, Guy served as a Research Associate at VBL Therapeutics (NASDAQ: VBLT), a biotechnology company focused on the discovery, development and commercialization of first in class treatments for immune-inflammatory diseases and cancer. Guy led research in the fields of cancer and cardiovascular diseases, managing the development of novel drug delivery systems. In addition, Guy is also the Founder and Managing Director of The French Horn Fund, a nonprofit impact fund that invests in social enterprises and special-needs populations in Israel. Guy holds a B.Sc in Biotechnology and a Ph.D in Molecular Biotechnology as part of the Academic-Corporate Partnership Program, Faculty of Life Sciences at Bar Ilan University, Israel.